Five Prime Therapeutics (NASDAQ:FPRX) Moves On Wedbush Initiation. How Much Are Shares Worth?

May 18, 2018 - By Lindsey Sherman

Investors sentiment increased to 1.34 in Q4 2017. Its up 0.30, from 1.04 in 2017Q3. It is positive, as 21 investors sold Five Prime Therapeutics, Inc. shares while 29 reduced holdings. 24 funds opened positions while 43 raised stakes. 25.47 million shares or 6.30% more from 23.96 million shares in 2017Q3 were reported.

Florida-based State Board Of Administration Of Florida Retirement Sys has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Fifth Third State Bank owns 300 shares for 0% of their portfolio. Pnc Fin Gp holds 6 shares. Wellington Management Gru Limited Liability Partnership reported 2.98 million shares. Assetmark, a California-based fund reported 18 shares. Td Asset Management holds 11,500 shares. Citigroup Inc holds 0% or 70,667 shares in its portfolio. Adage Prns Gru Limited Company owns 1.30M shares. California Pub Employees Retirement System stated it has 22,000 shares or 0% of all its holdings. Barclays Public Llc holds 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 7,033 shares. Tiaa Cref Invest Mngmt Limited Liability Company holds 0% or 63,756 shares. Amundi Pioneer Asset Inc reported 202,800 shares. Envestnet Asset Mngmt Inc holds 52 shares or 0% of its portfolio. New York-based D E Shaw & has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Parallax Volatility Advisers Lp has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 4,524 shares.

Why Has Wedbush Given Five Prime Therapeutics (NASDAQ:FPRX) a $17.0000 Price Target

Wedbush analyst has initiated coverage with a Hold rating on Five Prime Therapeutics (NASDAQ:FPRX) today and set a price target of $17.0000. The company’s shares opened today at 18.35.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Ratings Coverage

Among 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Five Prime Therapeutics has $60 highest and $20 lowest target. $35’s average target is 90.74% above currents $18.35 stock price. Five Prime Therapeutics had 5 analyst reports since February 15, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, February 28 by BMO Capital Markets. The firm has “Buy” rating by Jefferies given on Thursday, March 1. As per Thursday, February 15, the company rating was maintained by Guggenheim. Nomura maintained the shares of FPRX in report on Wednesday, February 28 with “Buy” rating.

The stock decreased 2.91% or $0.55 during the last trading session, reaching $18.35. About 52,605 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 52.34% since May 18, 2017 and is downtrending. It has underperformed by 63.89% the S&P500.

Analysts await Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report earnings on August, 14. They expect $-1.33 EPS, up 15.82 % or $0.25 from last year’s $-1.58 per share. After $-0.63 actual EPS reported by Five Prime Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 111.11 % negative EPS growth.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $646.09 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

More recent Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news were published by: which released: “Goldman Sachs Starts Five Prime Therapeutics (FPRX) at Neutral” on May 10, 2018. Also published the news titled: “Premarket analyst action – healthcare” on May 18, 2018.‘s news article titled: “Five Prime Therapeutics’ (FPRX) CEO Aron Knickerbocker on Q1 2018 Results – Earnings Call Transcript” with publication date: May 13, 2018 was also an interesting one.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: